Casdin Capital

**Signal Note: Casdin Capital initiates $391M position in GeneDx** Casdin's substantial entry into WGSWW (GeneDx's warrant vehicle) signals confidence in the rare disease diagnostics platform following its 2021 acquisition by Invitae; the $391M commitment suggests conviction in near-term clinical/commercial inflection, likely tied to expansion of exome/genome sequencing adoption in pediatric rare disease workups where GeneDx maintains leading market share. This thesis aligns with Casdin's typical genomics infrastructure plays, though the timing of this position warrants monitoring against potential Invitae strategic announcements or diagnostic reimbursement developments.

# Signal Note: Casdin Capital Initiates $205M Position in RVMD **Summary:** Casdin's entry into Revolution Medicines signals confidence in the company's RAS(ON) program, likely driven by upcoming clinical catalysts in KRAS-mutant cancers where the addressable market exceeds $10B. The ~2.6M share position (approximately 4-5% stake) suggests conviction in near-term data readouts, potentially including Phase 2 updates in pancreatic or colorectal cancer expected in 2024-2025.

# Signal Note: Casdin Capital Initiates $144M Position in BLFS Casdin's $144M entry into Biolife Solutions—a leading developer of cell and tissue preservation technology—signals conviction in the expanding regenerative medicine and cell therapy market. BLFS's HypoThermosol preservation platform is critical infrastructure for the growing number of CAR-T, stem cell, and organ transplant programs, with near-term catalysts including expanded hospital adoption and partnership revenues. The position sizing suggests Casdin sees durable margin expansion as cell therapy volumes scale post-2024 clinical readouts across multiple sponsored programs.

# Signal Note: Casdin Capital Initiates $113.6M Position in Standard Biotools (LAB) Casdin's entry into LAB signals confidence in the company's microfluidics and single-cell analysis platform, which serves drug discovery and cell therapy workflows—critical infrastructure for genomics-driven R&D. The $113.6M stake (representing a substantial position) suggests conviction in LAB's TAM expansion as biotech increasingly adopts high-throughput phenotyping and functional genomics tools. Near-term catalysts to monitor include customer adoption metrics, gross margin trajectory, and any partnerships with major pharma conducting target validation.

**Signal Note: Casdin Capital Initiates $110M Position in Relay Therapeutics** Casdin's entry into RLAY suggests conviction in the company's precision oncology platform, likely driven by upcoming clinical catalysts in RLY-1971 (mutant-selective EGFR inhibitor for NSCLC) and earlier-stage programs targeting undrugged kinase mutations. The $110M stake—material for a single-name biotech position—indicates confidence in either near-term trial readouts or the addressable market potential of their structure-enabled drug discovery approach.

# Signal Note: Casdin Capital Entry into Structure Therapeutics Casdin's $81.7M initiation in GPCR-focused Structure suggests conviction in their lead program GPCR agonist for obesity/metabolic disease, a crowded but high-value segment. The timing likely reflects confidence in near-term clinical data or partnering catalysts, as Structure has multiple programs in early development stages. This represents a meaningful bet from a specialist investor with strong genomics/tools track record, though the position size is modest relative to typical large-cap biotech allocations.

# Signal Note: Casdin Capital Initiates $78.7M Illumina Position Casdin's entry into ILMN at ~$131/share suggests conviction in sequencing-as-infrastructure demand, likely driven by accelerating clinical genomics adoption and AI-enabled data analysis workflows. This move aligns with Casdin's genomics tools thesis and may signal confidence in ILMN's near-term margin expansion or market share gains in oncology/reproductive health testing where sequencing penetration remains sub-saturated.

# Signal Note: Casdin Capital Initiates $72.1M Position in Avidity Biosciences Casdin's entry into Avidity's RNA-targeting platform suggests conviction in the company's lead program, AVY-5104, an RNA-editing therapeutic for Duchenne muscular dystrophy (DMD), which is advancing toward IND/clinical data readouts in 2024-2025. The $72.1M stake (1M shares) from a genomics-focused investor indicates institutional validation of Avidity's modular RNA editing approach as differentiated versus competing modalities in a crowded neuromuscular disease space. Near-term catalysts include preclinical data disclosures and regulatory milestones for both DMD and potential expansion indications.

# Signal Note: Casdin Capital Initiates $44.4M Position in Beam Therapeutics Casdin's entry into BEAM likely reflects confidence in the company's lead program, BEAM-101 (exagamglogene autogedtemcel) for sickle cell disease, which achieved primary efficacy endpoints in Phase 1/2 and is advancing toward potential BLA submission in 2025. The $44.4M stake (1.6M shares) signals conviction in base editing technology as a differentiated approach versus competing CRISPR therapies, with near-term inflection points including regulatory feedback and competitive positioning against Vertex/CRISPR Therapeutics in ex vivo cell therapy.

**Signal Note: Casdin Capital Initiates $38.8M Position in Guardant Health** Casdin's entry into GH signals confidence in the company's liquid biopsy platform amid expanding clinical adoption and reimbursement tailwinds for ctDNA-based cancer screening and monitoring. The timing suggests conviction in near-term revenue acceleration from SHIELD-TL (multi-cancer early detection) and oncology monitoring applications, which have shown strong uptake in 2024. Given Casdin's track record in genomics infrastructure, this likely reflects confidence in GH's competitive moat and margin expansion potential as volumes scale.

**Signal Note: Casdin Capital Initiates $31.4M Position in Maze Therapeutics** Casdin's entry signals confidence in Maze's platform for rare genetic diseases, particularly its lead program in ALGS (Alagille syndrome), which targets NOTCH2 stabilization—a novel mechanism in a ~5,000 patient U.S. market with limited approved options. The $31.4M stake likely reflects conviction ahead of upcoming clinical milestones, potentially including Phase 2 data readouts expected in 2024-2025 that could validate target engagement and clinical benefit in a disease with significant unmet need.

# Signal Note: Casdin Capital Entry into DNLI Casdin's $30.4M initiation in Denali suggests confidence in the company's neurodegenerative pipeline, likely driven by upcoming Phase 2 data for DNL788 (tau/neuroinflammation) and DNL126 (Parkinson's disease), both expected in 2024-2025. The biotech-focused investor's entry at current valuation (stock ~$16.50) indicates potential asymmetric risk/reward ahead of clinical readouts that could validate Denali's tau-targeting platform.

**Signal Note: Casdin Capital Initiates $29.8M ALNY Position** Casdin's entry into Alnylam signals confidence in the RNAi platform's commercial expansion beyond rare genetic diseases into larger indications—likely driven by recent label expansions (e.g., vutrisiran for ATTR-CM, givosiran for acute intermittent porphyria) and pipeline progress in cardiometabolic conditions. The $29.8M stake is material for a tools-focused investor, suggesting conviction in near-term revenue inflection or M&A optionality as Alnylam scales manufacturing capacity post-COVID.

**Signal Note: Casdin Capital Initiates $26.7M Position in Neurogene** Casdin's entry suggests conviction in Neurogene's gene therapy pipeline, particularly NGN-401 (GM1 gangliosidosis) and NGN-901 (Krabbe disease), both ultra-rare lysosomal storage disorders with limited treatment options and potential for accelerated regulatory pathways. Key catalysts include Phase 1/2 data readouts expected in 2024-2025 and FDA interactions around breakthrough designation status. The position size ($26.7M at ~5% of shares) indicates material commitment but reflects typical early-stage gene therapy risk.

# Signal Note: Casdin Capital Initiates 10x Genomics Position Casdin's $22.8M entry into TXG signals conviction in single-cell analysis tools as genomics infrastructure matures. 10x's core strengths in spatial transcriptomics and multiomics platforms remain foundational for target discovery and biomarker validation across oncology and immunology pipelines, particularly as cell-level resolution becomes standard in drug development. No near-term catalyst evident; position likely reflects longer-term thesis on consolidation of genomics workflows around established platforms.